AKR1C3-IN-4-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEAKR1C3-IN-4Cat.No.:HY-138557CASNo.:1284180-11-5分?式:C??H??F?NO?分?量:281.23作?靶點(diǎn):Others作?通路:Others儲(chǔ)存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(355.58mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM3.5558mL17.7790mL35.5581mL5mM0.7112mL3.5558mL7.1116mL10mM0.3556mL1.7779mL3.5558mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(protectfromlight)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(8.89mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(8.89mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(8.89mM);ClearsolutionBIOLOGICALACTIVITY?物活性AKR1C3-IN-4?種有效的，選擇性醛酮還原酶1C3(AKR1C3)抑制劑，IC50為0.56μM。AKR1C3-IN-4具有?于去勢(shì)抵抗性前列腺癌(CRPC)研究的潛?。IC50&TargetIC50:0.56μM(AKR1C3)and15.1μM(AKR1C2)[1]體外研究AKR1C3-IN-4hasanIC50of15.1μMforAKR1C2[1].REFERENCES[1].AdegokeOAdeniji,etal.Developmentofpotentandselectiveinhibitorsofaldo-ketoreductase1C3(type517β-hydroxysteroiddehydrogenase)basedonN-phenyl-aminobenzoatesandtheirstructure-activityrelationships.JMedChem.2012Mar8;55(5):2311-23.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;02